Form 4: Celldex Therapeutics Executive Exercises Options and Sells Shares

Elizabeth Crowley, SR. VP & CPDO of Celldex Therapeutics, exercised stock options and sold shares on June 7, 2024.

Summary

• On June 7, 2024, Elizabeth Crowley, SR. VP & CPDO of Celldex Therapeutics, exercised incentive stock options to acquire 7,500 shares at $10.38 and 7,500 shares at $9.0165.
• Following the exercise of these options, Ms. Crowley sold 15,000 shares of common stock at a weighted average price of $35.0582, with prices ranging from $34.86 to $35.59.
• After these transactions, Ms. Crowley directly owns 9,074 shares of Celldex Therapeutics common stock and holds options for 76,500 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of stock option exercise and share sale by an executive. The sale could be for personal financial reasons and doesn't necessarily reflect a negative view of the company.

Positives

• The exercise of options and subsequent sale of shares indicates that Ms. Crowley is converting her stock options into cash, which could be seen as a positive sign of her confidence in the company's future.

Negatives

• The sale of 15,000 shares by a senior executive could be interpreted negatively by some investors, although it is a relatively small percentage of the total outstanding shares.

Risks

• Executive stock sales can sometimes create short-term downward pressure on the stock price.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Investors often monitor these transactions for insights into management's perspective on the company's valuation and future prospects. It's important to consider the size and frequency of these transactions in relation to the executive's overall holdings and the company's trading volume.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options as a significant component.
• The vesting schedules and exercise prices of these options are typically structured to align executive incentives with long-term shareholder value creation.
• Comparing Ms. Crowley's stock option grants and vesting schedule to those of executives at comparable biotechnology companies (e.g., Regeneron, Amgen, or Biogen) would provide a benchmark for assessing the competitiveness and appropriateness of her compensation package.

Stakeholder Impact

• The transaction could have a minor short-term impact on shareholders due to the sale of shares in the market.

Key Dates